metformin has been researched along with c-peptide in 139 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 6 (4.32) | 18.7374 |
1990's | 30 (21.58) | 18.2507 |
2000's | 45 (32.37) | 29.6817 |
2010's | 50 (35.97) | 24.3611 |
2020's | 8 (5.76) | 2.80 |
Authors | Studies |
---|---|
Andrews, WJ; Boreham, C; Boyd, K; Hadden, DR; Rogers, C | 1 |
Buscema, M; Italia, S; Mazzarino, S; Rabuazzo, AM; Sangiorgio, L; Squatrito, S; Trischitta, V; Vigneri, R | 1 |
Birkeland, KI; Chatzipanagiotou, F; Hanssen, KF; Vaaler, S | 1 |
Hermann, LS; Karlsson, JE; Sjöstrand, A | 1 |
Bird, DM; Cameron, DP; Ma, A; McIntyre, HD; Paterson, CA; Ravenscroft, PJ | 1 |
Landin, K; Smith, U; Tengborn, L | 1 |
Huupponen, R; Karvonen, I; Rytömaa, K; Sotaniemi, EA; Vierimaa, E; Vuoti, MJ | 1 |
Andersen, PH; Beck-Nielsen, H; Hother-Nielsen, O; Pedersen, O; Schmitz, O | 1 |
Augustin-Pascalis, I; Mirouze, J; Orsetti, A; Richard, JL; Rodier, M | 1 |
Peacock, I; Selby, C; Tattersall, RB; Watts, R | 1 |
Branca, S; Coco, R; Damante, G; Del Campo, F; Di Vincenzo, S; Ferlito, S; Fichera, C | 1 |
Bonora, E; Bosello, O; Butturini, U; Capretti, L; Cigolini, M; Coscelli, C; Zancanaro, C; Zavaroni, I | 1 |
Peacock, I; Tattersall, RB | 1 |
Chow, CC; Cockram, CS; Sorensen, JP; Tsang, LW | 1 |
Chiasson, JL; Hunt, JA; Josse, RG; Palmason, C; Rodger, NW; Ross, SA; Ryan, EA; Tan, MH; Wolever, TM | 1 |
Bitzén, PO; Hermann, LS; Kjellström, T; Lindgärde, F; Melander, A; Scherstén, B | 1 |
Ceriello, A; Consoli, G; D'Onofrio, F; De Rosa, N; Giugliano, D; Minei, A; Quatraro, A | 1 |
Kuusi, T; Lahdenperä, S; Taskinen, MR; Tilly-Kiesi, M; Vuorinen-Markkola, H | 1 |
Nagi, DK; Yudkin, JS | 1 |
Lefèbvre, PJ; Letiexhe, MR; Scheen, AJ | 1 |
Clauson, P; Efendic, S; Karlander, S; Steen, L | 1 |
Adalar, N; Bayraktar, M; Van Thiel, DH | 1 |
Espinosa-Campos, J; Fanghänel, G; Sánchez-Reyes, L; Sotres, D; Trujillo, C | 1 |
Convent, G; Gudat, U; Heinemann, L | 1 |
Ambrosi, F; Filipponi, P; Gregorio, F; Manfrini, S; Santucci, A | 1 |
Carlsen, J; Køber, L; Snorgaard, O | 1 |
Aiache, JM; Cardot, JM; Saffar, F | 1 |
Bell, DS; Ovalle, F | 3 |
Arai, K; Hori, M; Imano, E; Kajimoto, Y; Kanda, T; Motomura, M; Nakatani, Y; Nishida, T; Yamasaki, Y | 1 |
Heikkilä, M; Nikkilä, K; Ryysy, L; Tulokas, T; Vanamo, R; Yki-Järvinen, H | 1 |
Boyages, S; Carter, J; Colagiuri, S; Donnelly, T; Hopkins, H; Kidson, W; Moffitt, P; Moses, R; Slobodniuk, R | 1 |
Bak, MI; Czyzyk, A; Dworak, A; Zapecka-Dubno, B | 1 |
Avilés-Santa, L; Raskin, P; Sinding, J | 1 |
Coppini, A; Erle, G; Lora, L; Lovise, S; Marchetti, P; Merante, D; Stocchiero, C | 1 |
Golay, A; Lehmann, T; Morel, Y; Pasik, C; Perneger, T; Reaven, GM; Vadas, L | 1 |
Kruszynska, YT; Mulford, MI; Olefsky, JM; Yu, JG | 1 |
Clouâtre, Y | 1 |
Fritsche, A; Häring, HU; Schmülling, RM; Stumvoll, M | 1 |
Egan, JW; Einhorn, D; Mathisen, AL; Rendell, M; Rosenzweig, J; Schneider, RL | 1 |
Djordjević, PB; Jevtović, T; Kocić, G; Kocić, R; Mikić, D; Pavlović, D; Radenković, S; Stojanović, M | 1 |
Holst, JJ; Madsbad, S; Taskiran, M; Toft-Nielsen, MB; Zander, M | 1 |
Arslanian, S; Jones, KL; Park, JS; Peterokova, VA; Tomlinson, MJ | 1 |
Banerji, MA; Bastian, W; Castells, S; Taha, DR; Umpaichitra, V | 1 |
Abbink, EJ; Jansen van Rosendaal, A; Lutterman, JA; Pickkers, P; Russel, FG; Smits, P; Tack, CJ | 1 |
Born, J; Fehm, HL; Fruehwald-Schultes, B; Kern, W; Oltmanns, KM; Peters, A; Sopke, S; Toschek, B | 1 |
Banerji, MA; Castells, S; Umpaichitra, V | 1 |
Avilés-Santa, ML; Raskin, P; Strowig, SM | 1 |
Bohme, P; Cugnardey, N; Delbachian, I; Drouin, P; Guerci, B; Lehert, P; Meyer, L | 1 |
Grellner, WJ; Harris, WS; Isley, WL; Klein, S; Miles, JM; Windsor, S; Wooldridge, D | 1 |
Binnert, C; Giusti, V; Seematter, G; Tappy, L | 1 |
Cox, J; Elkeles, RS; Elwig, C; Poulter, C; Valabhji, J; Watson, M | 1 |
Beck-Nielsen, H; Henriksen, JE; Hother-Nielsen, O; Poulsen, MK | 1 |
Battaglia, C; Gamba, O; Genazzani, AD; Malavasi, B; Strucchi, C; Tortolani, F | 1 |
de Boer, H; Jansen, M; Koerts, J; Verschoor, L | 1 |
Dagalp, K; Deveci, S; Gulsen, M; Isik, AT; Kadayifci, A; Ozgurtas, T; Tuzun, A; Uygun, A; Yesilova, Z | 1 |
Guevara, M; Guevara-Aguirre, J; Mihic, M; Modi, P; Saavedra, J | 1 |
Leyck Dieken, MG; Pfeiffer, AF; Rochlitz, H; Rudovich, NN | 1 |
Komiya, I; Kouki, T; Nakachi, A; Takasu, N; Tamanaha, T; Tawata, M | 1 |
Björnholm, M; Chibalin, AV; Hällsten, K; Heinonen, OJ; Karlsson, HK; Lönnqvist, F; Nuutila, P; Tsuchida, H; Virtanen, KA; Zierath, JR | 1 |
Brunetti, P; Gori, M; Pagano, G; Perriello, G; Turco, C | 1 |
Brunetti, P; Charbonnel, B; Hanefeld, M; Matthews, DR; Schernthaner, G; Tan, MH; Urquhart, R | 1 |
Ahrén, B; Foley, JE; Pacini, G; Schweizer, A | 1 |
Issa, M; Lake, B; Melis, R; Roberts, VL; Stewart, J | 1 |
Carr, RD; Deacon, CF; Holst, J; Krarup, T; Madsbad, S; Ryskjaer, J; Vilsbøll, T | 1 |
Hanusch-Enserer, U; Kautzky-Willer, A; Ludvik, B; Pacini, G; Prager, R; Tura, A; Wagner, OF; Winzer, C | 1 |
Frandsen, M; Lund, SS; Parving, HH; Pedersen, O; Schalkwijk, CG; Smidt, UM; Stehouwer, CD; Tarnow, L; Vaag, A | 1 |
Carlsen, SM; Kjøtrød, SB; Romundstad, P; Sunde, A; von Düring, V | 1 |
Bellatreccia, A; Comaschi, M; Demicheli, A; Di Pietro, C; Mariz, S | 1 |
Basu, A; Basu, R; Chandramouli, V; Cohen, O; Dicke, B; Landau, BR; Norby, B; Rizza, RA; Shah, P | 2 |
Ahrén, B; Foley, JE; Pacini, G; Schweizer, A; Tura, A | 1 |
Hexeberg, S; Lindberg, FA | 1 |
Abdollahi, M; Ahmadi, H; Ansari, G; Kajbaf, F; Khajavi, MR; Khalili, H; Mojtahedzadeh, M; Najafi, A; Rouini, MR | 1 |
Bunck, MC; Cornér, A; Deng, W; Diamant, M; Eliasson, B; Heine, RJ; Kendall, DM; Malloy, JL; Shaginian, RM; Smith, U; Taskinen, MR; Yki-Järvinen, H | 1 |
Alejandro, R; Bernetti, K; Brieva, S; Cayetano, SM; Echevarria, L; Esteve, C; Estrada, EJ; Froud, T; Nicora, E; Ricordi, C; Valacchi, F; Velazquez, O | 1 |
Figenschau, Y; Jorde, R | 1 |
Charpentier, G; Halimi, S | 1 |
Daleke, D; Keltner, Z; Meyer, JA; Reid, GE; Sima, AA; Spence, DM; Subasinghe, W | 1 |
Möhlig, M; Otto, B; Pfeiffer, AF; Pivovarova, O; Rudovich, N; Spranger, J; Weickert, MO | 1 |
Benfeldt, E; Blomberg, M; Jeppesen, EM; Skovby, F | 1 |
Anand, A; Atignal, A; Iyer, H; Khedkar, A; Krishnamurthy, S; Savale, S; Verma, M | 1 |
Chen, MJ; Jovanovic, A; Taylor, R | 1 |
Isasi, CR; Wylie-Rosett, J | 1 |
Erem, C; Fidan, E; Karahan, C; Kocak, M; Onder Ersoz, H; Yilmaz, H; Yilmaz, M | 1 |
Knop, FK | 1 |
Bell, DS; Dharmalingam, M; Kumar, S; Sawakhande, RB | 1 |
Horowitz, M; Jones, KL; Ma, J; Rayner, CK | 1 |
Florez, JC; Goldberg, RB; Jablonski, KA; Kahn, SE; Majithia, AR; Mather, KJ; McAteer, JB | 1 |
Bunck, MC; Cornér, A; Diamant, M; Eliasson, B; Heine, RJ; Shaginian, RM; Smith, U; Taskinen, MR; Yki-Järvinen, H | 1 |
Davies, MJ; Goldstein, BJ; Golm, GT; Johnson, J; Kaufman, KD; Teng, R; Williams-Herman, D; Xu, L | 1 |
Bianchi, L; Bonaventura, A; Carbone, A; Cicero, AF; Derosa, G; Fogari, E; Maffioli, P; Ragonesi, PD; Romano, D | 1 |
Andreeff, M; Broglio, K; Busaidy, N; Cabanillas, ME; Ensor, J; Escalante, C; Faderl, S; Kantarjian, H; Konopleva, M; Lavis, V; O'Brien, S; Thomas, DA; Vu, K; Yeung, SC | 1 |
Bianchi, L; Bonaventura, A; Carbone, A; Cicero, AF; Derosa, G; Fogari, E; Franzetti, I; Maffioli, P; Querci, F; Romano, D | 1 |
Cree-Green, M; Mizokami-Stout, K; Nadeau, KJ | 1 |
George, P; McCrimmon, RJ | 1 |
Barrett, HL; Callaway, LK; Coat, S; De Blasio, MJ; Dekker Nitert, M; Gatford, KL; Hague, WM; Houda, CM; McIntyre, HD; Owens, JA; Rowan, JA | 1 |
Boggess, KA; Hickman, MA; McBride, R; Strauss, R | 1 |
Coester, HV; Forst, T; Hincelin-Méry, A; Kapitza, C; Poitiers, F; Ruus, P | 1 |
Arai, K; Hirao, K; Hirao, S; Hirao, T; Maeda, H; Sirabe, S; Yamamoto, R; Yamauchi, M | 1 |
Adams, J; Cersosimo, E; DeFronzo, RA; Garduno-Garcia, Jde J; Solis-Herrera, C; Triplitt, C | 1 |
Carbone, A; Ciccarelli, L; Derosa, G; Fogari, E; Franzetti, IG; Maffioli, P; Piccinni, MN; Querci, F | 1 |
Bhatt, MP; Ha, KS; Kim, YM; Lim, YC | 1 |
Balas, B; Balena, R; Boldrin, M; Bolli, GB; Charbonnel, B; Gastaldelli, A; Ratner, R; Rosenstock, J | 1 |
Badaru, A; Beavers, D; Dabelea, D; Dolan, L; Imperatore, G; Klingensmith, GJ; Lawrence, JM; Marcovina, S; Mayer-Davis, EJ; Pihoker, C; Rodriguez, BL | 1 |
Boden, G; Chalamandaris, AG; Duchesne, D; Henry, RR; Iqbal, N; List, J; Mudaliar, S; Smith, S | 1 |
Hirata, T; Maruyama, T; Morimoto, J; Shimada, A | 1 |
Lerchbaum, E; Obermayer-Pietsch, B; Pieber, T; Schweighofer, N; Schwetz, V; Trummer, O | 1 |
Ferrannini, E; Mari, A; Polidori, D | 1 |
Apseloff, G; Atiee, G; Bush, MA; Collins, DA; Corsino, L; Feldman, PL; Gillmor, D; McMullen, SL; Morrow, L; Nunez, DJ | 1 |
Engelsberger, I; Warncke, K | 1 |
Abt, M; Fuerst-Recktenwald, S; Häring, HU; Heise, T; Hompesch, M; Kapitza, C; Magnone, MC; Morrow, L; Ramsauer, M | 1 |
Hirshberg, B; Iqbal, N; Lu, J; Sjöstrand, M | 1 |
Aaboe, K; Akram, S; Deacon, CF; Holst, JJ; Krarup, T; Madsbad, S | 1 |
Alizadeh, A; Bahar, A; Hashemi-Soteh, MB; Kashi, Z; Mahrooz, A; Masoumi, P | 1 |
Ali, S; Crosbie, EJ; Gilmour, K; Kitchener, HC; Kitson, S; McVey, R; Pemberton, P; Renehan, AG; Roberts, C; Sivalingam, VN | 1 |
Brønden, A; Christensen, M; Hansen, M; Holst, JJ; Knop, FK; Rehfeld, JF; Rohde, U; Sonne, DP; Toräng, S; Vilsbøll, T | 1 |
de la Peña, A; Del Prato, S; Karanikas, CA; Ludvik, B; Mari, A; Milicevic, Z; Pechtner, V; Shurzinske, L | 1 |
Bergman, A; Erion, DM; Kazierad, DJ; Lee, DS; Rolph, T; Somayaji, V; Tan, B | 1 |
Abiru, N; Ando, T; Horie, I; Kawakami, A; Shigeno, R | 1 |
Chamnan, P; Han, KA; Kim, DJ; Kim, ES; Kim, EY; Kim, M; Kim, SH; Kwon, S; Lee, KW; Lee, MK; Lim, S; Moon, MK; Wongtanate, M; Yoon, KH; Yu, J | 1 |
Baranov, O; Deacon, CF; Holst, JJ; Kahle, M; Nauck, MA | 1 |
Arslanian, S; Bacha, F; Caprio, S; El Ghormli, L; Goland, R; Haymond, MW; Levitsky, L; Nadeau, KJ; White, NH; Willi, SM | 1 |
Carlsson, B; Chen, H; Ekholm, E; Hansen, L; Hirshberg, B; Iqbal, N; Johnsson, E | 1 |
Demir, S; Sargin, M; Temizkan, S | 1 |
Beysel, S; Cakal, E; Caliskan, M; Kizilgul, M; Ucan, B; Unsal, IO | 1 |
Adel, MM; Fogelfeld, L; Guerra, Y; Shah, M; Tahsin, B | 1 |
Ahmad, T; Fung, EB; Hussain, R; Killilea, DW; Lal, A | 1 |
Abenavoli, L; Aludwan, M; Fagoonee, S; Kobyliak, N; Komisarenko, I; Kyriienko, D; Pellicano, R | 1 |
Banerji, MA; Barzilay, J; Cohen, RM; Gonzalez, EV; Ismail-Beigi, F; Kahn, SE; Lachin, JM; Mather, KJ; Raskin, P; Rasouli, N; Utzschneider, KM; Wexler, DJ; Younes, N | 1 |
Bednarski, M; Kieć-Kononowicz, K; Kotańska, M; Kuder, K; Mika, K; Pociecha, K; Pomierny, B; Sapa, J; Szafarz, M; Szczepańska, K | 1 |
Cobelli, C; Dalla Man, C; Visentin, R | 1 |
Hu, Y; Huang, G; Huang, J; Leslie, RD; Li, X; Liu, B; Liu, Z; Tang, X; Wang, X; Xiang, Y; Xie, Z; Yan, X; Zhang, Z; Zhou, H; Zhou, Z | 1 |
Fang, C; He, C; Huang, Y; Li, J; Sang, G; Tao, S; Zhou, B | 1 |
3 review(s) available for metformin and c-peptide
Article | Year |
---|---|
FGFR3 mutations and the skin: report of a patient with a FGFR3 gene mutation, acanthosis nigricans, hypochondroplasia and hyperinsulinemia and review of the literature.
Topics: Acanthosis Nigricans; Adolescent; Blood Glucose; C-Peptide; Dwarfism; Female; Gonadotropin-Releasing Hormone; Human Growth Hormone; Humans; Hyperinsulinism; Keratosis, Seborrheic; Metformin; Point Mutation; Receptor, Fibroblast Growth Factor, Type 3 | 2010 |
Insulin resistance in type 2 diabetic youth.
Topics: Adolescent; Body Mass Index; C-Peptide; Child; Diabetes Mellitus, Type 2; Exercise Tolerance; Female; Glucagon; Glucose Intolerance; Glucose Tolerance Test; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin Secretion; Islets of Langerhans; Male; Metformin; Obesity; Phenotype; Young Adult | 2012 |
Potential role of non-insulin adjunct therapy in Type 1 diabetes.
Topics: Blood Glucose; Body Weight; C-Peptide; Diabetes Mellitus, Type 1; Dipeptidyl-Peptidase IV Inhibitors; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Islet Amyloid Polypeptide; Male; Metformin; Randomized Controlled Trials as Topic | 2013 |
96 trial(s) available for metformin and c-peptide
Article | Year |
---|---|
Insulin, glibenclamide or metformin treatment for non insulin dependent diabetes: heterogenous responses of standard measures of insulin action and insulin secretion before and after differing hypoglycaemic therapy.
Topics: Blood Glucose; Body Mass Index; C-Peptide; Diabetes Mellitus, Type 2; Glucose Clamp Technique; Glyburide; Glycated Hemoglobin; Glycosuria; Humans; Insulin; Insulin Resistance; Insulin Secretion; Metabolic Clearance Rate; Metformin; Middle Aged; Radioisotope Dilution Technique; Tritium | 1992 |
Comparison of combined therapies in treatment of secondary failure to glyburide.
Topics: Blood Glucose; Body Weight; C-Peptide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Therapy, Combination; Eating; Fasting; Glyburide; Glycated Hemoglobin; Humans; Insulin, Isophane; Metformin; Middle Aged; Obesity | 1992 |
Prospective comparative study in NIDDM patients of metformin and glibenclamide with special reference to lipid profiles.
Topics: Administration, Oral; Adult; Aged; Blood Glucose; Body Weight; C-Peptide; Cholesterol; Diabetes Mellitus, Type 2; Female; Glyburide; Humans; Insulin; Insulin Secretion; Lipids; Lipoproteins; Male; Metformin; Middle Aged; Prospective Studies; Triglycerides | 1991 |
Metformin increases insulin sensitivity and basal glucose clearance in type 2 (non-insulin dependent) diabetes mellitus.
Topics: Adult; Aged; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Female; Glucose; Humans; Insulin; Insulin Resistance; Liver; Male; Metformin; Middle Aged; Prospective Studies | 1991 |
Insulin and sulphonylurea in the therapy of type 2 diabetes.
Topics: Aged; Blood Glucose; C-Peptide; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glipizide; Glyburide; Glycated Hemoglobin; Humans; Insulin; Lipids; Male; Metformin; Middle Aged; Placebos; Random Allocation; Sulfonylurea Compounds | 1990 |
Metformin improves peripheral but not hepatic insulin action in obese patients with type II diabetes.
Topics: Blood Glucose; C-Peptide; Circadian Rhythm; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Double-Blind Method; Fasting; Humans; Insulin; Lactates; Lactic Acid; Liver; Metformin; Middle Aged; Obesity | 1989 |
Serum C-peptide after 6 months on glibenclamide remains higher than during insulin treatment.
Topics: Adult; Aged; C-Peptide; Diabetes Mellitus, Type 2; Female; Glyburide; Humans; Insulin; Male; Metformin; Middle Aged; Time Factors | 1987 |
The difficult choice of treatment for poorly controlled maturity onset diabetes: tablets or insulin?
Topics: Adult; Aged; Attitude to Health; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glyburide; Humans; Insulin, Long-Acting; Male; Metformin; Middle Aged; Prospective Studies; Random Allocation; Tablets | 1984 |
Comparison of insulin with or without continuation of oral hypoglycemic agents in the treatment of secondary failure in NIDDM patients.
Topics: Analysis of Variance; Biomarkers; Blood Glucose; Body Mass Index; C-Peptide; Cholesterol; Cholesterol, HDL; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Fructosamine; Gliclazide; Glipizide; Glyburide; Glycated Hemoglobin; Hexosamines; Humans; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Treatment Failure; Triglycerides | 1995 |
The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus. A multicenter controlled clinical trial.
Topics: Acarbose; Blood Glucose; C-Peptide; Combined Modality Therapy; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glycated Hemoglobin; Glycoside Hydrolase Inhibitors; Humans; Insulin; Lipids; Male; Metformin; Middle Aged; Sulfonylurea Compounds; Trisaccharides | 1994 |
Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations. A double-blind controlled study.
Topics: Adult; Aged; Blood Glucose; Blood Pressure; Body Weight; C-Peptide; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glyburide; Humans; Insulin; Lipids; Male; Metformin; Middle Aged | 1994 |
Metformin for obese, insulin-treated diabetic patients: improvement in glycaemic control and reduction of metabolic risk factors.
Topics: Blood Glucose; Blood Pressure; C-Peptide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucagon; Glycated Hemoglobin; Homeostasis; Humans; Islets of Langerhans; Lipids; Male; Metformin; Middle Aged; Obesity; Prospective Studies; Risk Factors; Single-Blind Method | 1993 |
Effects of gemfibrozil on low-density lipoprotein particle size, density distribution, and composition in patients with type II diabetes.
Topics: Apolipoproteins B; Blood Glucose; C-Peptide; Cholesterol, HDL; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Gemfibrozil; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Lipoproteins, LDL; Lipoproteins, VLDL; Male; Metformin; Middle Aged; Phospholipids; Placebos; Triglycerides | 1993 |
Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects. A study of two ethnic groups.
Topics: Albuminuria; Asia; Biomarkers; Blood Glucose; C-Peptide; Cardiovascular Diseases; Cholesterol; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Ethnicity; Fructosamine; Hexosamines; Humans; Insulin; Insulin Resistance; Islets of Langerhans; Metabolic Clearance Rate; Metformin; Plasminogen Activator Inhibitor 1; Platelet Aggregation; Risk Factors; Triglycerides; United Kingdom; White People | 1993 |
Short administration of metformin improves insulin sensitivity in android obese subjects with impaired glucose tolerance.
Topics: Adult; Blood Glucose; Body Constitution; C-Peptide; Cross-Over Studies; Double-Blind Method; Female; Glucose Intolerance; Glucose Tolerance Test; Humans; Hypoglycemic Agents; Insulin; Male; Metformin; Obesity | 1995 |
Daytime glibenclamide and bedtime NPH insulin compared to intensive insulin treatment in secondary sulphonylurea failure: a 1-year follow-up.
Topics: Aged; Albuminuria; Analysis of Variance; Blood Glucose; Body Mass Index; C-Peptide; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Drug Administration Schedule; Female; Glyburide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin, Isophane; Insulin, Regular, Pork; Male; Metformin; Middle Aged; Sulfonylurea Compounds; Treatment Failure; Triglycerides | 1996 |
A comparison of acarbose versus metformin as an adjuvant therapy in sulfonylurea-treated NIDDM patients.
Topics: Acarbose; Adult; Blood Glucose; C-Peptide; Cholesterol; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Metformin; Middle Aged; Sulfonylurea Compounds; Triglycerides; Trisaccharides | 1996 |
Metformin's effects on glucose and lipid metabolism in patients with secondary failure to sulfonylureas.
Topics: Blood Glucose; Body Mass Index; C-Peptide; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Insulin; Lipids; Male; Metformin; Middle Aged; Obesity; Recombinant Proteins; Regression Analysis; Sulfonylurea Compounds; Treatment Failure; Triglycerides | 1996 |
Metformin and exercise: no additive effect on blood lactate levels in health volunteers.
Topics: Adult; Analysis of Variance; Blood Pressure; C-Peptide; Exercise; Heart Rate; Humans; Hydrogen-Ion Concentration; Hypoglycemic Agents; Insulin; Lactates; Male; Metformin; Oxidation-Reduction; Pyruvates | 1997 |
Meformin, plasma glucose and free fatty acids in type II diabetic out-patients: results of a clinical study.
Topics: Blood Glucose; Body Constitution; Body Mass Index; C-Peptide; Cholesterol; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fasting; Fatty Acids, Nonesterified; Female; Gliclazide; Glyburide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Lipoprotein(a); Male; Metformin; Middle Aged; Regression Analysis; Sex Characteristics | 1997 |
The effect of metformin on blood pressure and metabolism in nondiabetic hypertensive patients.
Topics: Adult; Aged; Analysis of Variance; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory; C-Peptide; Dose-Response Relationship, Drug; Double-Blind Method; Female; Glucose Tolerance Test; Humans; Hypertension; Hypoglycemic Agents; Insulin; Lipids; Male; Metformin; Middle Aged | 1997 |
Influence of food on glycemia, insulin, C-peptide and glucagon levels in diabetic patients treated with antidiabetic metformin at steady-state.
Topics: Adult; Aged; Area Under Curve; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Diet; Female; Glucagon; Humans; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged | 1997 |
Metformin lowers lipoprotein(a) levels.
Topics: Aged; C-Peptide; Diabetes Mellitus; Female; Humans; Hypoglycemic Agents; Lipoprotein(a); Male; Metformin; Middle Aged; Retrospective Studies | 1998 |
Effect of troglitazone on microalbuminuria in patients with incipient diabetic nephropathy.
Topics: Aged; Albuminuria; Blood Glucose; Blood Pressure; C-Peptide; Cholesterol; Cholesterol, HDL; Chromans; Creatinine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Thiazoles; Thiazolidinediones; Triglycerides; Troglitazone | 1998 |
Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus. A randomized, controlled trial.
Topics: Albuminuria; Blood Glucose; Blood Pressure; C-Peptide; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Therapy, Combination; Follow-Up Studies; Glyburide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Lipids; Metformin; Middle Aged; Weight Gain | 1999 |
Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with type 2 diabetes.
Topics: Australia; Blood Glucose; C-Peptide; Carbamates; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Fasting; Fatty Acids, Nonesterified; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Piperidines; Triglycerides | 1999 |
Effect of oral antidiabetic agents on plasma amylin level in patients with non-insulin-dependent diabetes mellitus (type 2).
Topics: Adult; Amyloid; Blood Glucose; C-Peptide; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Female; Glyburide; Humans; Hypoglycemic Agents; Insulin; Islet Amyloid Polypeptide; Male; Metformin | 1999 |
Effects of metformin in patients with poorly controlled, insulin-treated type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial.
Topics: Blood Glucose; Body Weight; C-Peptide; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Energy Intake; Hemoglobin A; Humans; Hypoglycemic Agents; Insulin; Lipids; Metformin; Obesity; Statistics, Nonparametric | 1999 |
A comparison of preconstituted, fixed combinations of low-dose glyburide plus metformin versus high-dose glyburide alone in the treatment of type 2 diabetic patients.
Topics: Blood Glucose; Body Weight; C-Peptide; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Combinations; Fasting; Female; Glyburide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Postprandial Period; Time Factors | 1999 |
Metformin treatment leads to an increase in basal, but not insulin-stimulated, glucose disposal in obese patients with impaired glucose tolerance.
Topics: Blood Glucose; C-Peptide; Double-Blind Method; Female; Fructosamine; Glucose Intolerance; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin Secretion; Male; Metformin; Obesity; Placebos | 1999 |
A comparison of troglitazone and metformin on insulin requirements in euglycemic intensively insulin-treated type 2 diabetic patients.
Topics: Blood Glucose; Body Weight; C-Peptide; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Chromans; Circadian Rhythm; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Therapy, Combination; Fatty Acids, Nonesterified; Female; Fructosamine; Humans; Hypoglycemic Agents; Insulin; Insulin Infusion Systems; Male; Metformin; Middle Aged; Thiazoles; Thiazolidinediones; Triglycerides; Troglitazone | 1999 |
Intensive insulin therapy combined with metformin in obese type 2 diabetic patients.
Topics: Body Mass Index; Body Weight; C-Peptide; Cholesterol; Diabetes Mellitus; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucose Tolerance Test; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Lipoproteins; Male; Metformin; Middle Aged; Obesity; Placebos; Triglycerides | 2000 |
Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group.
Topics: Adult; Aged; Blood Glucose; C-Peptide; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Humans; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Pioglitazone; Placebos; Thiazoles; Thiazolidinediones | 2000 |
Additive glucose-lowering effects of glucagon-like peptide-1 and metformin in type 2 diabetes.
Topics: Blood Glucose; C-Peptide; Cross-Over Studies; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Therapy, Combination; Female; Gastrointestinal Hormones; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptides; Glycated Hemoglobin; Humans; Infusions, Parenteral; Insulin; Insulin Secretion; Kinetics; Male; Metformin; Middle Aged; Peptide Fragments; Placebos; Research Design | 2001 |
Effect of metformin in pediatric patients with type 2 diabetes: a randomized controlled trial.
Topics: Adolescent; Blood Glucose; Body Mass Index; C-Peptide; Child; Diabetes Mellitus, Type 2; Double-Blind Method; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Placebos; Racial Groups | 2002 |
Beta-cell response to intravenous glucagon in African-American and Hispanic children with type 2 diabetes mellitus.
Topics: Adolescent; Adult; Black or African American; Blood Glucose; C-Peptide; Child; Diabetes Mellitus, Type 2; Fasting; Female; Glucagon; Glycated Hemoglobin; Hispanic or Latino; Humans; Hypoglycemic Agents; Injections, Intravenous; Insulin; Islets of Langerhans; Male; Metformin; Pancreatic Function Tests | 2002 |
Vascular effects of glibenclamide vs. glimepiride and metformin in Type 2 diabetic patients.
Topics: Acetylcholine; Adult; Aged; Blood Flow Velocity; Blood Pressure; Body Mass Index; Body Weight; C-Peptide; Cross-Over Studies; Diabetes Mellitus, Type 2; Diazoxide; Dipyridamole; Double-Blind Method; Female; Forearm; Glyburide; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Sulfonylurea Compounds; Vasodilation | 2002 |
Short-term treatment with metformin decreases serum leptin concentration without affecting body weight and body fat content in normal-weight healthy men.
Topics: Adipose Tissue; Adult; Blood Pressure; Body Weight; C-Peptide; Diabetes Mellitus; Glucagon; Humans; Hydrocortisone; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin-Like Growth Factor Binding Protein 3; Insulin-Like Growth Factor I; Leptin; Male; Metformin; Obesity; Reference Values | 2002 |
Comparison of insulin monotherapy and combination therapy with insulin and metformin or insulin and troglitazone in type 2 diabetes.
Topics: Adult; Age of Onset; Aged; Body Mass Index; C-Peptide; Chromans; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Lipids; Lipoproteins; Male; Metformin; Middle Aged; Racial Groups; Texas; Thiazoles; Thiazolidinediones; Troglitazone | 2002 |
The benefits of metformin therapy during continuous subcutaneous insulin infusion treatment of type 1 diabetic patients.
Topics: Adult; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 1; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Infusion Systems; Male; Metformin; Placebos; Time Factors | 2002 |
Nocturnal and postprandial free fatty acid kinetics in normal and type 2 diabetic subjects: effects of insulin sensitization therapy.
Topics: Adult; Blood Glucose; C-Peptide; Chromans; Circadian Rhythm; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Female; Food; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Kinetics; Lipolysis; Male; Metformin; Middle Aged; Placebos; Thiazoles; Thiazolidinediones; Troglitazone | 2003 |
Effect of metformin on insulin sensitivity and insulin secretion in female obese patients with normal glucose tolerance.
Topics: Adult; Blood Glucose; Body Mass Index; C-Peptide; Cross-Over Studies; Female; Glucose Clamp Technique; Humans; Insulin; Insulin Secretion; Metformin; Obesity; Placebos; Reference Values | 2003 |
The combined effect of triple therapy with rosiglitazone, metformin, and insulin aspart in type 2 diabetic patients.
Topics: Aged; Blood Glucose; Blood Pressure; C-Peptide; Circadian Rhythm; Diabetes Mellitus; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucose Clamp Technique; Glycated Hemoglobin; Glycolysis; Humans; Hypoglycemic Agents; Insulin; Insulin Aspart; Male; Metformin; Middle Aged; Obesity; Rosiglitazone; Thiazolidinediones | 2003 |
Metformin administration modulates and restores luteinizing hormone spontaneous episodic secretion and ovarian function in nonobese patients with polycystic ovary syndrome.
Topics: 17-alpha-Hydroxyprogesterone; Adult; Androstenedione; Area Under Curve; Blood Glucose; C-Peptide; Estradiol; Female; Follicle Stimulating Hormone; Humans; Insulin; Luteinizing Hormone; Menstrual Cycle; Metformin; Obesity; Ovary; Polycystic Ovary Syndrome; Testosterone | 2004 |
Metformin in the treatment of patients with non-alcoholic steatohepatitis.
Topics: Adult; Blood Glucose; C-Peptide; Female; Hepatitis; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Metformin; Middle Aged; Steatorrhea; Treatment Outcome | 2004 |
Beneficial effects of addition of oral spray insulin (Oralin) on insulin secretion and metabolic control in subjects with type 2 diabetes mellitus suboptimally controlled on oral hypoglycemic agents.
Topics: Administration, Oral; Adult; Aged; Blood Glucose; C-Peptide; Cross-Over Studies; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Therapy, Combination; Female; Glyburide; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Male; Metformin; Middle Aged; Prospective Studies; Statistics, Nonparametric | 2004 |
Enhancement of early- and late-phase insulin secretion and insulin sensitivity by the combination of repaglinide and metformin in type 2 diabetes mellitus.
Topics: Adult; Aged; C-Peptide; Carbamates; Cohort Studies; Cross-Over Studies; Diabetes Mellitus, Type 2; Drug Synergism; Drug Therapy, Combination; Female; Glucose Clamp Technique; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Male; Metformin; Middle Aged; Piperidines; Placebos; Time Factors | 2004 |
Effects of metformin and rosiglitazone treatment on insulin signaling and glucose uptake in patients with newly diagnosed type 2 diabetes: a randomized controlled study.
Topics: Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Gene Expression Regulation; Glucose; Humans; Hypoglycemic Agents; Insulin; Islets of Langerhans; Metformin; Phosphatidylinositol 3-Kinases; Phosphorylation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Rosiglitazone; Thiazolidinediones | 2005 |
Effects of two different glibenclamide dose-strengths in the fixed combination with metformin in patients with poorly controlled T2DM: a double blind, prospective, randomised, cross-over clinical trial.
Topics: Adult; Blood Glucose; Body Mass Index; C-Peptide; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Fasting; Female; Food; Glyburide; Glycated Hemoglobin; History, 18th Century; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Lactic Acid; Male; Metformin; Middle Aged; Prospective Studies | 2004 |
Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes.
Topics: Adult; Aged; C-Peptide; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Gliclazide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Lipids; Male; Metformin; Middle Aged; Pioglitazone; Reproducibility of Results; Safety; Thiazolidinediones; Treatment Failure; Treatment Outcome | 2005 |
Improved meal-related beta-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year.
Topics: Adamantane; Area Under Curve; Blood Glucose; Body Mass Index; C-Peptide; Dipeptidyl Peptidase 4; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Islets of Langerhans; Male; Metformin; Middle Aged; Nitriles; Placebos; Protease Inhibitors; Pyrrolidines; Vildagliptin | 2005 |
Triple therapy with glimepiride in patients with type 2 diabetes mellitus inadequately controlled by metformin and a thiazolidinedione: results of a 30-week, randomized, double-blind, placebo-controlled, parallel-group study.
Topics: Adult; Aged; Blood Glucose; Body Mass Index; C-Peptide; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Lipids; Male; Metformin; Middle Aged; Pioglitazone; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones; Time Factors | 2005 |
Insulin sensitivity during oral glucose tolerance test and its relations to parameters of glucose metabolism and endothelial function in type 2 diabetic subjects under metformin and thiazolidinedione.
Topics: Blood Glucose; Body Weight; C-Peptide; Cell Adhesion Molecules; Chromans; Diabetes Mellitus, Type 2; Drug Monitoring; Female; Glucose Tolerance Test; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Metformin; Middle Aged; Proinsulin; Thiazolidinediones; Troglitazone | 2006 |
Targeting hyperglycaemia with either metformin or repaglinide in non-obese patients with type 2 diabetes: results from a randomized crossover trial.
Topics: Adiponectin; Biomarkers; Blood Glucose; Body Weight; C-Peptide; C-Reactive Protein; Carbamates; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Patient Compliance; Piperidines; Prospective Studies; Waist-Hip Ratio | 2007 |
C-reactive protein levels are unaffected by metformin during pretreatment and an IVF cycle in women with polycystic ovary syndrome.
Topics: Adult; Androgens; Biomarkers; Body Mass Index; C-Peptide; C-Reactive Protein; Double-Blind Method; Female; Fertilization in Vitro; Humans; Hypoglycemic Agents; Infertility, Female; Metformin; Oocyte Retrieval; Ovulation Induction; Polycystic Ovary Syndrome; Pregnancy; Prospective Studies; Time Factors | 2008 |
Effects of pioglitazone in combination with metformin or a sulfonylurea compared to a fixed-dose combination of metformin and glibenclamide in patients with type 2 diabetes.
Topics: Adult; C-Peptide; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glyburide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin-Secreting Cells; Male; Metformin; Pioglitazone; Safety; Thiazolidinediones | 2007 |
Comparison of the effects of pioglitazone and metformin on hepatic and extra-hepatic insulin action in people with type 2 diabetes.
Topics: Blood Glucose; Body Mass Index; C-Peptide; Diabetes Mellitus, Type 2; Diet, Diabetic; Double-Blind Method; Drug Administration Schedule; Fatty Acids, Nonesterified; Female; Glucagon; Gluconeogenesis; Glucose Clamp Technique; Glycerol; Glycogenolysis; Humans; Hypoglycemic Agents; Infusions, Intravenous; Insulin; Kinetics; Liver; Male; Metformin; Middle Aged; Pioglitazone; Placebos; Thiazolidinediones | 2008 |
Improved meal-related insulin processing contributes to the enhancement of B-cell function by the DPP-4 inhibitor vildagliptin in patients with type 2 diabetes.
Topics: Adamantane; C-Peptide; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Insulin; Insulin-Secreting Cells; Male; Metformin; Middle Aged; Nitriles; Postprandial Period; Proinsulin; Pyrrolidines; Treatment Outcome; Vildagliptin | 2007 |
How does blood glucose control with metformin influence intensive insulin protocols? Evidence for involvement of oxidative stress and inflammatory cytokines.
Topics: Adult; Aged; Blood Glucose; C-Peptide; Clinical Protocols; Cytokines; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Insulin; Intensive Care Units; Metformin; Middle Aged; Nitric Oxide; Oxidative Stress; Systemic Inflammatory Response Syndrome; Young Adult | 2008 |
One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial.
Topics: Arginine; Blood Glucose; Body Mass Index; C-Peptide; Diabetes Mellitus, Type 2; Exenatide; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin Secretion; Insulin-Secreting Cells; Insulin, Long-Acting; Kinetics; Male; Metformin; Middle Aged; Peptides; Venoms | 2009 |
Combined treatment of intrapancreatic autologous bone marrow stem cells and hyperbaric oxygen in type 2 diabetes mellitus.
Topics: Adult; Animals; Blood Glucose; Bone Marrow Cells; C-Peptide; Combined Modality Therapy; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Hyperbaric Oxygenation; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Stem Cell Transplantation; Transplantation, Autologous | 2008 |
Supplementation with cholecalciferol does not improve glycaemic control in diabetic subjects with normal serum 25-hydroxyvitamin D levels.
Topics: Adult; Aged; Blood Glucose; C-Peptide; Calcifediol; Calcium; Cholecalciferol; Diabetes Mellitus, Type 2; Dietary Supplements; Female; Fructosamine; Glycated Hemoglobin; Humans; Insulin; Insulin, Long-Acting; Male; Metformin; Middle Aged; Young Adult | 2009 |
Earlier triple therapy with pioglitazone in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Homeostasis; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Lipids; Male; Metformin; Middle Aged; Pioglitazone; Proinsulin; Sulfonylurea Compounds; Thiazolidinediones | 2009 |
Effect of meglitinides on postprandial ghrelin secretion pattern in type 2 diabetes mellitus.
Topics: Adult; Aged; Benzamides; Blood Glucose; Body Mass Index; C-Peptide; Carbamates; Cross-Over Studies; Diabetes Mellitus, Type 2; Eating; Feeding Behavior; Ghrelin; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Metformin; Middle Aged; Piperidines; Reference Values; Single-Blind Method | 2010 |
A dose range finding study of novel oral insulin (IN-105) under fed conditions in type 2 diabetes mellitus subjects.
Topics: Administration, Oral; Adult; Aged; C-Peptide; Diabetes Mellitus, Type 2; Drug Administration Schedule; Female; Humans; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Postprandial Period; Tablets; Treatment Outcome | 2010 |
Utilizing the second-meal effect in type 2 diabetes: practical use of a soya-yogurt snack.
Topics: Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Dietary Proteins; Fatty Acids, Nonesterified; Female; Humans; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Postprandial Period; Yogurt | 2010 |
The effects of rosiglitazone and metformin on inflammation and endothelial dysfunction in patients with type 2 diabetes mellitus.
Topics: Adult; C-Peptide; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Endothelial Cells; Female; Humans; Interleukin-6; Male; Metformin; Middle Aged; Rosiglitazone; Thiazolidinediones; Tumor Necrosis Factor-alpha | 2011 |
Triple oral fixed-dose diabetes polypill versus insulin plus metformin efficacy demonstration study in the treatment of advanced type 2 diabetes (TrIED study-II).
Topics: Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Drug Combinations; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Patient Satisfaction; Pioglitazone; Postprandial Period; Prospective Studies; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome | 2011 |
Association of the SLC30A8 missense polymorphism R325W with proinsulin levels at baseline and after lifestyle, metformin or troglitazone intervention in the Diabetes Prevention Program.
Topics: Adult; C-Peptide; Cation Transport Proteins; Chromans; Diabetes Mellitus; Diabetes Mellitus, Type 2; Female; Humans; Insulin; Male; Metformin; Middle Aged; Polymorphism, Genetic; Proinsulin; Thiazolidinediones; Troglitazone; Zinc Transporter 8 | 2011 |
Effects of exenatide on measures of β-cell function after 3 years in metformin-treated patients with type 2 diabetes.
Topics: Adult; Aged; Blood Glucose; Body Weight; C-Peptide; Diabetes Mellitus, Type 2; Exenatide; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Glargine; Insulin-Secreting Cells; Insulin, Long-Acting; Male; Metformin; Middle Aged; Peptides; Venoms | 2011 |
Effect of initial combination therapy with sitagliptin and metformin on β-cell function in patients with type 2 diabetes.
Topics: Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Glucose Tolerance Test; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin-Secreting Cells; Male; Metformin; Middle Aged; Postprandial Period; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2012 |
Vildagliptin added to metformin on β-cell function after a euglycemic hyperinsulinemic and hyperglycemic clamp in type 2 diabetes patients.
Topics: Adamantane; Blood Glucose; Body Mass Index; C-Peptide; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fasting; Female; Glucose Clamp Technique; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin Secretion; Insulin-Secreting Cells; Male; Metformin; Middle Aged; Nitriles; Pyrrolidines; Vildagliptin; Weight Loss | 2012 |
A randomized controlled trial of an intensive insulin regimen in patients with hyperglycemic acute lymphoblastic leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Blood Glucose; Burkitt Lymphoma; C-Peptide; Cyclophosphamide; Dexamethasone; Disease-Free Survival; Doxorubicin; Female; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin, Long-Acting; Male; Metformin; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Prospective Studies; Thiazolidinediones; Treatment Outcome; Vincristine; Young Adult | 2012 |
Effects of a combination of sitagliptin plus metformin vs metformin monotherapy on glycemic control, β-cell function and insulin resistance in type 2 diabetic patients.
Topics: Blood Glucose; C-Peptide; C-Reactive Protein; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Exercise; Fasting; Female; Glucagon; Glucose Clamp Technique; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Resistance; Insulin-Secreting Cells; Italy; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2012 |
Maternal and neonatal circulating markers of metabolic and cardiovascular risk in the metformin in gestational diabetes (MiG) trial: responses to maternal metformin versus insulin treatment.
Topics: Adult; Blood Glucose; C-Peptide; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, HDL; Diabetes, Gestational; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Infant, Newborn; Insulin; Leptin; Metformin; Pregnancy; Risk Factors; Triglycerides | 2013 |
Metformin compared with insulin in the treatment of pregnant women with overt diabetes: a randomized controlled trial.
Topics: Adult; C-Peptide; Diabetes Mellitus, Type 2; Diabetes, Gestational; Female; Fetal Blood; Humans; Hypoglycemic Agents; Insulin; Metformin; Patient Satisfaction; Pregnancy; Pregnancy in Diabetics | 2013 |
Pharmacodynamic characteristics of lixisenatide once daily versus liraglutide once daily in patients with type 2 diabetes insufficiently controlled on metformin.
Topics: Adult; Aged; C-Peptide; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Resistance; Female; Glucagon; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hyperglycemia; Hyperinsulinism; Hypoglycemic Agents; Incretins; Injections, Subcutaneous; Liraglutide; Male; Metformin; Middle Aged; Peptides | 2013 |
Glimepiride strongly enhances the glucose-lowering effect in triple oral antidiabetes therapy with sitagliptin and metformin for Japanese patients with type 2 diabetes mellitus.
Topics: Aged; Aged, 80 and over; Blood Glucose; Body Mass Index; C-Peptide; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Japan; Male; Metformin; Middle Aged; Prospective Studies; Pyrazines; Sitagliptin Phosphate; Sulfonylurea Compounds; Treatment Outcome; Triazoles | 2013 |
Mechanisms of glucose lowering of dipeptidyl peptidase-4 inhibitor sitagliptin when used alone or with metformin in type 2 diabetes: a double-tracer study.
Topics: Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Fasting; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Insulin; Metformin; Pyrazines; Sitagliptin Phosphate; Triazoles | 2013 |
Variation in inflammatory markers and glycemic parameters after 12 months of exenatide plus metformin treatment compared with metformin alone: a randomized placebo-controlled trial.
Topics: Aged; Arginine; Biomarkers; Blood Glucose; Body Mass Index; Body Weight; C-Peptide; Chimerin Proteins; Diabetes Mellitus, Type 2; Diet; Double-Blind Method; Drug Therapy, Combination; Endpoint Determination; Exenatide; Female; Glucose Clamp Technique; Humans; Hypoglycemic Agents; Inflammation; Insulin Resistance; Male; Metformin; Middle Aged; Peptides; Resistin; Risk Factors; Serpins; Venoms | 2013 |
A direct comparison of long- and short-acting GLP-1 receptor agonists (taspoglutide once weekly and exenatide twice daily) on postprandial metabolism after 24 weeks of treatment.
Topics: Adolescent; Adult; Aged; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Exenatide; Female; Glucagon; Glucagon-Like Peptide-1 Receptor; Glucose Tolerance Test; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Male; Meals; Metformin; Middle Aged; Peptides; Postprandial Period; Receptors, Glucagon; Treatment Outcome; Venoms | 2014 |
Restoring Insulin Secretion (RISE): design of studies of β-cell preservation in prediabetes and early type 2 diabetes across the life span.
Topics: Adolescent; Adult; Aged; Arginine; Blood Glucose; C-Peptide; Child; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Gastroplasty; Glucagon-Like Peptide 1; Glucose Clamp Technique; Glucose Tolerance Test; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin Secretion; Insulin-Secreting Cells; Liraglutide; Male; Metformin; Middle Aged; Prediabetic State; Young Adult | 2014 |
Changes in insulin sensitivity and insulin secretion with the sodium glucose cotransporter 2 inhibitor dapagliflozin.
Topics: Adult; Aged; Benzhydryl Compounds; Blood Glucose; C-Peptide; Creatinine; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucose Tolerance Test; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin Secretion; Male; Metformin; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2014 |
Canagliflozin, a sodium glucose co-transporter 2 inhibitor, improves model-based indices of beta cell function in patients with type 2 diabetes.
Topics: Adult; Aged; Blood Glucose; C-Peptide; Canagliflozin; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucosides; Humans; Insulin-Secreting Cells; Least-Squares Analysis; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Sodium-Glucose Transporter 2; Sulfonylurea Compounds; Thiophenes; Time Factors; Triazoles | 2014 |
Gut hormone pharmacology of a novel GPR119 agonist (GSK1292263), metformin, and sitagliptin in type 2 diabetes mellitus: results from two randomized studies.
Topics: Blood Glucose; C-Peptide; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Gastrointestinal Hormones; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Insulin; Male; Mesylates; Metformin; Middle Aged; Oxadiazoles; Peptide YY; Prognosis; Pyrazines; Receptors, G-Protein-Coupled; Sitagliptin Phosphate; Triazoles | 2014 |
Safety, efficacy and weight effect of two 11β-HSD1 inhibitors in metformin-treated patients with type 2 diabetes.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Adult; Aged; Austria; Blood Glucose; Body Weight; C-Peptide; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Female; Germany; Glucose Tolerance Test; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Lipids; Male; Metformin; Middle Aged; Risk Assessment; Treatment Outcome; United States | 2014 |
Saxagliptin improves glycemic control by modulating postprandial glucagon and C-peptide levels in Chinese patients with type 2 diabetes.
Topics: Adamantane; Asian People; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Fasting; Female; Glucagon; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin-Secreting Cells; Male; Metformin; Middle Aged; Postprandial Period | 2014 |
Restoration of the insulinotropic effect of glucose-dependent insulinotropic polypeptide contributes to the antidiabetic effect of dipeptidyl peptidase-4 inhibitors.
Topics: C-Peptide; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Glucose Clamp Technique; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin; Insulin Secretion; Insulin-Secreting Cells; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Triazoles; Up-Regulation | 2015 |
Measuring the biological effect of presurgical metformin treatment in endometrial cancer.
Topics: Aged; Aged, 80 and over; Blood Glucose; C-Peptide; Carcinoma, Endometrioid; Endometrial Hyperplasia; Endometrial Neoplasms; Enzyme-Linked Immunosorbent Assay; Female; Humans; Hypoglycemic Agents; Hysterectomy; Immunohistochemistry; Insulin; Insulin Resistance; Ki-67 Antigen; Metformin; Middle Aged; Myometrium; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Invasiveness; Phosphatidylinositol 3-Kinases; Phosphorylation; Preoperative Care; Proto-Oncogene Proteins c-akt; TOR Serine-Threonine Kinases; Treatment Outcome | 2016 |
Cholecystokinin-Induced Gallbladder Emptying and Metformin Elicit Additive Glucagon-Like Peptide-1 Responses.
Topics: Adult; Blood Glucose; C-Peptide; Cholecystokinin; Double-Blind Method; Gallbladder; Gallbladder Emptying; Gastrins; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Insulin; Male; Metformin; Organ Size; Ultrasonography; Young Adult | 2016 |
Effects of multiple ascending doses of the glucagon receptor antagonist PF-06291874 in patients with type 2 diabetes mellitus.
Topics: Adult; Aged; Alanine Transaminase; Amino Acids; Aspartate Aminotransferases; beta-Alanine; Blood Glucose; C-Peptide; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Fasting; Female; Glucagon; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Pyrazoles; Receptors, Glucagon; Sulfonylurea Compounds | 2016 |
Efficacy and safety of initial combination therapy with gemigliptin and metformin compared with monotherapy with either drug in patients with type 2 diabetes: A double-blind randomized controlled trial (INICOM study).
Topics: Adult; Aged; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Fasting; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Piperidones; Proinsulin; Pyrimidines; Republic of Korea; Thailand; Treatment Outcome | 2017 |
Addition of a dipeptidyl peptidase-4 inhibitor, sitagliptin, to ongoing therapy with the glucagon-like peptide-1 receptor agonist liraglutide: A randomized controlled trial in patients with type 2 diabetes.
Topics: Adult; Aged; Blood Glucose; C-Peptide; Cross-Over Studies; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Liraglutide; Male; Metformin; Middle Aged; Sitagliptin Phosphate; Treatment Outcome | 2017 |
COMBINED TREATMENT WITH SAXAGLIPTIN PLUS DAPAGLIFLOZIN REDUCES INSULIN LEVELS BY INCREASED INSULIN CLEARANCE AND IMPROVES β-CELL FUNCTION.
Topics: Adamantane; Aged; Area Under Curve; Benzhydryl Compounds; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Dipeptides; Double-Blind Method; Drug Therapy, Combination; Female; Glucose Tolerance Test; Glucosides; Humans; Hypoglycemic Agents; Insulin; Insulin-Secreting Cells; Male; Metformin; Middle Aged; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2017 |
Effect of short-term prednisone on beta-cell function in subjects with type 2 diabetes mellitus and healthy subjects.
Topics: Adult; Blood Glucose; C-Peptide; Case-Control Studies; Diabetes Mellitus, Type 2; Female; Humans; Insulin; Insulin Resistance; Insulin-Secreting Cells; Male; Metformin; Middle Aged; Prednisone; Young Adult | 2020 |
Combination therapy with saxagliptin and vitamin D for the preservation of β-cell function in adult-onset type 1 diabetes: a multi-center, randomized, controlled trial.
Topics: Adult; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Insulin; Metformin; Vitamin D | 2023 |
40 other study(ies) available for metformin and c-peptide
Article | Year |
---|---|
Relationship between blood pressure and in vivo action of insulin in type II (non-insulin-dependent) diabetic subjects.
Topics: Antihypertensive Agents; Blood Pressure; C-Peptide; Diabetes Mellitus, Type 2; Diet, Diabetic; Female; Glucagon; Glucose Clamp Technique; Glyburide; Glycated Hemoglobin; Humans; Hypertension; Infusions, Intravenous; Insulin; Male; Metformin; Middle Aged; Regression Analysis | 1992 |
Treating insulin resistance in hypertension with metformin reduces both blood pressure and metabolic risk factors.
Topics: Blood Glucose; C-Peptide; Cholesterol; Cholesterol, LDL; Fibrinogen; Humans; Hypertension; Insulin; Insulin Resistance; Male; Metformin; Middle Aged; Pilot Projects; Plasminogen Inactivators; Risk Factors; Tissue Plasminogen Activator; Triglycerides | 1991 |
[Secondary failure of oral antidiabetics. Value of intravenous insulin infusions].
Topics: Administration, Oral; Adult; Aged; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glyburide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Infusion Systems; Male; Metformin; Middle Aged | 1986 |
Effect of metformin on blood glucose, insulin and C-peptide responses to glucagon in non-insulin dependent diabetics.
Topics: Aged; Blood Glucose; C-Peptide; Diabetes Mellitus; Glucagon; Humans; Insulin; Male; Metformin; Middle Aged; Peptides; Time Factors | 1983 |
Lack of effect of intravenous metformin on plasma concentrations of glucose, insulin, C-peptide, glucagon and growth hormone in non-diabetic subjects.
Topics: Adult; Blood Glucose; C-Peptide; Female; Glucagon; Growth Hormone; Humans; Injections, Intravenous; Insulin; Male; Metformin; Middle Aged | 1984 |
Lowering C-peptide levels and renoprotective therapy.
Topics: C-Peptide; Contraindications; Humans; Hypoglycemic Agents; Kidney Diseases; Metformin | 2000 |
Effect of four-week metformin treatment on plasma and erythrocyte antioxidative defense enzymes in newly diagnosed obese patients with type 2 diabetes.
Topics: Blood Glucose; C-Peptide; Catalase; Diabetes Mellitus; Diabetes Mellitus, Type 2; Erythrocytes; Fructosamine; Glutathione; Glutathione Peroxidase; Humans; Hydrogen Peroxide; Hypoglycemic Agents; In Vitro Techniques; Lipid Peroxidation; Metformin; Middle Aged; Obesity; Oxidative Stress; Reference Values; Superoxide Dismutase | 2000 |
Autoantibodies in children with type 2 diabetes mellitus.
Topics: Adolescent; Autoantibodies; C-Peptide; Diabetes Mellitus, Type 2; Fasting; Glutamate Decarboxylase; Humans; Hypoglycemic Agents; Insulin; Insulin Antibodies; Metformin | 2002 |
Type 2 diabetes presenting as diabetic ketoacidosis in adolescence.
Topics: Acanthosis Nigricans; Adolescent; Blood Glucose; Body Weight; C-Peptide; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Metformin; Obesity | 2003 |
Prevention of weight gain in type 2 diabetes requiring insulin treatment.
Topics: Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Pilot Projects; Sulfonylurea Compounds; Weight Gain | 2004 |
Outcomes of initiation of therapy with once-daily combination of a thiazolidinedione and a biguanide at an early stage of type 2 diabetes.
Topics: Body Mass Index; C-Peptide; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Metformin; Regression Analysis; Retrospective Studies; Rosiglitazone; Thiazolidinediones; Treatment Outcome | 2004 |
Low-dose metformin improves hyperglycaemia related to myotonic dystrophy.
Topics: Blood Glucose; C-Peptide; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Metformin; Middle Aged; Myotonic Dystrophy; Sulfonylurea Compounds | 2005 |
Long-term glycaemic efficacy and weight changes associated with thiazolidinediones when added at an advanced stage of type 2 diabetes.
Topics: Administration, Oral; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Follow-Up Studies; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Injections; Insulin; Insulin Resistance; Long-Term Care; Metformin; Middle Aged; Sulfonylurea Compounds; Thiazolidinediones; Treatment Failure; Treatment Outcome; Weight Gain | 2006 |
Plasma dipeptidyl peptidase-IV activity in patients with type-2 diabetes mellitus correlates positively with HbAlc levels, but is not acutely affected by food intake.
Topics: Blood Glucose; Body Mass Index; C-Peptide; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Eating; Fasting; Female; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged | 2006 |
[New data on hypoglycemia risk and beta cell function].
Topics: C-Peptide; Cross-Over Studies; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Exenatide; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin-Secreting Cells; Insulin, Long-Acting; Metformin; Peptides; Randomized Controlled Trials as Topic; Risk Factors; Time Factors; Venoms; Weight Gain; Weight Loss | 2007 |
[Insulin-using woman with type 2 diabetes and weight problems].
Topics: C-Peptide; Caloric Restriction; Diabetes Mellitus, Type 2; Diet, Carbohydrate-Restricted; Exercise Therapy; Female; Humans; Hypertension; Hypoglycemic Agents; Hypothyroidism; Insulin; Metformin; Middle Aged; Overweight; Weight Loss | 2008 |
Effects of pioglitazone and metformin on NEFA-induced insulin resistance in type 2 diabetes.
Topics: Blood Glucose; Body Mass Index; C-Peptide; Diabetes Mellitus, Type 2; Fat Emulsions, Intravenous; Fatty Acids, Nonesterified; Female; Glucagon; Gluconeogenesis; Glucose; Glucose Clamp Technique; Glycerol; Heparin; Humans; Insulin; Insulin Resistance; Male; Metformin; Middle Aged; Pioglitazone; Thiazolidinediones | 2008 |
Zinc-activated C-peptide resistance to the type 2 diabetic erythrocyte is associated with hyperglycemia-induced phosphatidylserine externalization and reversed by metformin.
Topics: Adenosine Triphosphate; Animals; Antibodies; C-Peptide; Diabetes Mellitus, Type 2; Erythrocytes; Exocytosis; Glucose; Humans; Hyperglycemia; Metformin; Phosphatidylserines; Rats; Spectrometry, Mass, Electrospray Ionization; Zinc | 2009 |
Considering options for attenuating postmeal glucose excursions.
Topics: Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Dietary Proteins; Fatty Acids, Nonesterified; Female; Humans; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Postprandial Period; Yogurt | 2010 |
Comment on: Chen et al. utilizing the second-meal effect in type 2 diabetes: practical use of a soya-yogurt snack. Diabetes Care 2010;33:2552–2554.
Topics: Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Dietary Proteins; Fatty Acids, Nonesterified; Female; Humans; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Postprandial Period; Randomized Controlled Trials as Topic; Yogurt | 2011 |
Comment on: Chen et al. Utilizing the second-meal effect in type 2 diabetes: practical use of a soya-yogurt snack. Diabetes Care 2010;33:2552-2554.
Topics: Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Dietary Proteins; Fatty Acids, Nonesterified; Female; Humans; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Postprandial Period; Yogurt | 2011 |
C-peptide activates AMPKα and prevents ROS-mediated mitochondrial fission and endothelial apoptosis in diabetes.
Topics: Aminoimidazole Carboxamide; AMP-Activated Protein Kinases; Animals; Apoptosis; C-Peptide; Cells, Cultured; Cytosol; Diabetes Mellitus, Experimental; Diabetic Angiopathies; Enzyme Activation; Glucose; Human Umbilical Vein Endothelial Cells; Humans; Male; Membrane Potential, Mitochondrial; Metformin; Mice; Mice, Inbred C57BL; Mitochondrial Dynamics; Reactive Oxygen Species | 2013 |
Correlates of treatment patterns among youth with type 2 diabetes.
Topics: Administration, Oral; Adolescent; Blood Glucose; Blood Glucose Self-Monitoring; C-Peptide; Child; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Life Style; Male; Metformin; Treatment Failure; Young Adult | 2014 |
Slowly progressive type 1 diabetes treated with metformin for five years after onset.
Topics: Autoantibodies; Autoantigens; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 1; Disease Progression; Glutamate Decarboxylase; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Iodide Peroxidase; Iron-Binding Proteins; Male; Metformin; Middle Aged | 2013 |
Metformin resistance alleles in polycystic ovary syndrome: pattern and association with glucose metabolism.
Topics: Adult; Ataxia Telangiectasia Mutated Proteins; C-Peptide; Drug Resistance; Female; Genetic Association Studies; Glucose; Glucose Tolerance Test; Humans; Insulin Resistance; Metformin; Organic Cation Transport Proteins; Organic Cation Transporter 1; Organic Cation Transporter 2; Polycystic Ovary Syndrome; Polymorphism, Single Nucleotide | 2014 |
[Difficult diagnosis in a 17-year-old patient: Type 1 diabetes? Type 2 diabetes? Or "double diabetes"?].
Topics: Adolescent; Autoantibodies; Blood Glucose; C-Peptide; Cation Transport Proteins; Comorbidity; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diagnosis, Differential; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Pediatric Obesity; Receptor-Like Protein Tyrosine Phosphatases, Class 8; Zinc Transporter 8 | 2014 |
The variant organic cation transporter 2 (OCT2)-T201M contribute to changes in insulin resistance in patients with type 2 diabetes treated with metformin.
Topics: C-Peptide; Diabetes Mellitus, Type 2; DNA; Female; Genetic Variation; Genotype; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Metformin; Middle Aged; Organic Cation Transport Proteins; Organic Cation Transporter 2; Polymorphism, Genetic | 2015 |
Differential effects of once-weekly glucagon-like peptide-1 receptor agonist dulaglutide and metformin on pancreatic β-cell and insulin sensitivity during a standardized test meal in patients with type 2 diabetes.
Topics: Adult; Aged; Area Under Curve; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Fasting; Female; Glucagon; Glucagon-Like Peptide-1 Receptor; Glucagon-Like Peptides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Immunoglobulin Fc Fragments; Insulin; Insulin Resistance; Insulin-Secreting Cells; Male; Metformin; Middle Aged; Postprandial Period; Recombinant Fusion Proteins; Treatment Outcome | 2016 |
Low-carbohydrate diet combined with SGLT2 inhibitor for refractory hyperglycemia caused by insulin antibodies.
Topics: Adamantane; Aged; Benzhydryl Compounds; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Diet, Carbohydrate-Restricted; Drug Therapy, Combination; Glucosides; Humans; Hypoglycemic Agents; Insulin; Insulin Antibodies; Insulin Resistance; Male; Metformin; Nitriles; Pyrrolidines; Sodium-Glucose Transporter 2 Inhibitors; Vildagliptin | 2016 |
Adiponectin, Insulin Sensitivity, β-Cell Function, and Racial/Ethnic Disparity in Treatment Failure Rates in TODAY.
Topics: Adiponectin; Adolescent; Black People; Blood Glucose; C-Peptide; Child; Diabetes Mellitus, Type 2; Drug Combinations; Ethnicity; Female; Glucose Tolerance Test; Health Status Disparities; Hispanic or Latino; Humans; Hypoglycemic Agents; Insulin Resistance; Life Style; Male; Metformin; Thiazoles; Treatment Failure; White People | 2017 |
C-Peptide Levels Predict the Effectiveness of Dipeptidyl Peptidase-4 Inhibitor Therapy.
Topics: Aged; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Prognosis; Retrospective Studies; Sitagliptin Phosphate; Treatment Outcome; Weight Loss | 2016 |
The effects of metformin in type 1 diabetes mellitus.
Topics: Adult; Biomarkers; Blood Glucose; Body Weight; C-Peptide; Case-Control Studies; Diabetes Mellitus, Type 1; Drug Therapy, Combination; Female; Follow-Up Studies; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Lipids; Male; Metabolic Syndrome; Metformin; Prognosis; Retrospective Studies | 2018 |
Effects of Treatment of Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes With Metformin Alone or in Combination With Insulin Glargine on β-Cell Function: Comparison of Responses In Youth And Adults.
Topics: Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Female; Glucose Intolerance; Glucose Tolerance Test; Humans; Insulin Glargine; Insulin Resistance; Male; Metformin; Middle Aged | 2019 |
Lack of Durable Improvements in β-Cell Function Following Withdrawal of Pharmacological Interventions in Adults With Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes.
Topics: Adult; Arginine; B-Lymphocytes; Blood Glucose; Body Weight; C-Peptide; Diabetes Mellitus, Type 2; Fasting; Female; Glucose Intolerance; Humans; Hypoglycemic Agents; Insulin Glargine; Insulin Resistance; Liraglutide; Male; Metformin; Middle Aged; Withholding Treatment | 2019 |
Zinc supplementation improves markers of glucose homeostasis in thalassaemia.
Topics: Adolescent; Adult; Biomarkers; Blood Glucose; C-Peptide; Child; Diabetes Complications; Diabetes Mellitus; Dietary Supplements; Female; Glucose Tolerance Test; Homeostasis; Humans; Hypoglycemic Agents; Insulin; Insulin-Secreting Cells; Iron Chelating Agents; Male; Metformin; Middle Aged; Pilot Projects; Thalassemia; Young Adult; Zinc; Zinc Sulfate | 2020 |
Vitamin D3 deficiency is associated with more severe insulin resistance and metformin use in patients with type 2 diabetes.
Topics: Adolescent; Adult; Aged; Body Mass Index; C-Peptide; Cholecalciferol; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Ergocalciferols; Female; Glycemic Control; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Metformin; Middle Aged; Obesity; Vitamin D Deficiency; Young Adult | 2020 |
Association of glycemia with insulin sensitivity and β-cell function in adults with early type 2 diabetes on metformin alone.
Topics: Blood Glucose; C-Peptide; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin-Secreting Cells; Metformin; Randomized Controlled Trials as Topic | 2021 |
Metabolic benefits of novel histamine H
Topics: Adipose Tissue; Animals; Body Weight; C-Peptide; Carrier Proteins; Cholesterol; Energy Intake; Feeding Behavior; Female; Glucose Tolerance Test; Histamine Agonists; Histamine Antagonists; Injections, Intraperitoneal; Insulin; Insulin Resistance; Leptin; Ligands; Metformin; Models, Animal; Obesity; Rats, Wistar; Receptors, Histamine H3; Triglycerides | 2021 |
A software interface for in silico testing of type 2 diabetes treatments.
Topics: Blood Glucose; C-Peptide; Computer Simulation; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin; Liraglutide; Metformin; Software | 2022 |
[Comparison of therapeutic effect of metformin hydrochloride/vildagliptin and liraglutide on type 2 diabetes mellitus in obese patients].
Topics: Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Liraglutide; Metformin; Obesity; Retrospective Studies; Treatment Outcome; Vildagliptin | 2023 |